Cover Image
市場調查報告書

全球類風濕性關節炎治療藥市場

Global Rheumatoid Arthritis Drugs Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 235961
出版日期 內容資訊 英文 94 Pages
訂單完成後即時交付
價格
Back to Top
全球類風濕性關節炎治療藥市場 Global Rheumatoid Arthritis Drugs Market 2014-2018
出版日期: 2014年07月14日 內容資訊: 英文 94 Pages
簡介

全球類風濕性關節炎治療藥市場在2013∼2018年,預計以年複合成長率4.09%擴大。類風濕性關節炎為慢性疾病,於引起手腕和手指,膝蓋等的疼痛和發炎。女性比男性容易發病3倍,遺傳的因素和環境的因素與類風濕性關節炎發病相關。

本報告提供全球類風濕性關節炎治療藥市場相關調查、各地區趨勢、到2018年的市場成長預測與課題、供應商的競爭趨勢與簡介等彙整。

第1章 摘要整理

第2章 簡稱

第3章 本報告的範圍

第4章 市場調查方法

第5章 簡介

第6章 市場環境

  • 市場概要
  • 市場規模與預測

第7章 主要藥物的競爭評估

第8章 波特的五力分析

第9章 各類別市場區隔

第10章 各地區市場區隔

第11章 購買標準

第12章 發病率和罹患率

  • 美國
  • 英國
  • 亞洲

第13章 開發平台概要

第14章 市場成長的促進要素

第15章 促進要素與其影響

第16章 市場課題

第17章 促進要素與課題的影響

第18章 市場趨勢

第19章 趨勢與其影響

第20章 供應商環境

  • 競爭模式
    • 主要消息
    • 合併、收購
    • 市場佔有率分析
    • 其他值得注意的供應商

第21章 主要供應商分析

  • AbbVie
  • Amgen
  • Bristol-Myers Squibb
  • F. Hoffmann La Roche
  • Janssen Pharmaceuticals
  • Pfizer

第22章 本系列的其他報告

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR3808

About Rheumatoid Arthritis

RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA.

TechNavio's analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Rheumatoid Arthritis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of RA that are available in the market. The Global Rheumatoid Arthritis Drugs market can be divided into two segments: Symptomatic and DMARDs.

TechNavio's report, the Global Rheumatoid Arthritis Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Rheumatoid Arthritis Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Janssen Pharmaceuticals Inc.
  • Pfizer Inc.

Other Prominent Vendors

  • AB Science SA
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Biogen Idec Inc.
  • Boehringer Ingelheim GmbH
  • Celgene Corp.
  • Daiichi Sankyo Co. Ltd.
  • Eli Lilly & Co.
  • GE Healthcare Co.
  • Genmab A/S
  • GSK plc
  • Incyte Corp.
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Novartis AG
  • Novo Nordisk A/S
  • Rigel Pharmaceuticals Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
  • UCB SA
  • Vertex Pharmaceuticals Inc.

Key Market Driver

  • Increasing Aging Population

For a full, detailed list, view our report.

Key Market Challenge

  • High Cost of RA Treatment

For a full, detailed list, view our report.

Key Market Trend

  • Increase in R&D Activities

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast

07. Competitive Assessment of Top Drugs

08. Five Forces Analysis

09. Market Segmentation by Category

10. Geographical Segmentation

11. Buying Criteria

12. Rate of Incidence and Prevalence

  • 12.1.1. US
  • 12.1.2. UK
  • 12.1.3. Asia

13. Pipeline Snapshot

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2013
  • 20.3. Other Prominent Vendors

21. Key Vendor Analysis

  • 21.1. AbbVie
    • 21.1.1. Key Facts
    • 21.1.2. Business Description
    • 21.1.3. Product Segmentation
    • 21.1.4. Revenue by Product Line
    • 21.1.5. Revenue Comparison 2012 and 2013
    • 21.1.6. Revenue by Geographical Segmentation
    • 21.1.7. Business Strategy
    • 21.1.8. Key Developments
    • 21.1.9. SWOT Analysis
    • 21.1.10. Strengths
    • 21.1.11. Weaknesses
    • 21.1.12. Opportunities
    • 21.1.13. Threats
  • 21.2. Amgen
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Product Segmentation by Revenue 2013
    • 21.2.4. Geographical Segmentation by Revenue 2013
    • 21.2.5. Business Strategy
    • 21.2.6. Key Information
    • 21.2.7. SWOT Analysis
    • 21.2.8. Strengths
    • 21.2.9. Weaknesses
    • 21.2.10. Opportunities
    • 21.2.11. Threats
  • 21.3. Bristol-Myers Squibb
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Product Segmentation
    • 21.3.4. Sales by Geography
    • 21.3.5. Business Strategy
    • 21.3.6. Key Information
    • 21.3.7. SWOT Analysis
    • 21.3.8. Strengths
    • 21.3.9. Weaknesses
    • 21.3.10. Opportunities
    • 21.3.11. Threats
  • 21.4. F. Hoffmann La Roche
    • 21.4.1. Key Facts
    • 21.4.2. Business Overview
    • 21.4.3. Business Segmentation
    • 21.4.4. Business Segmentation by Revenue 2012 and 2013
    • 21.4.5. Sales by Geography
    • 21.4.6. Business Strategy
    • 21.4.7. Key Information
    • 21.4.8. SWOT Analysis
    • 21.4.9. Strengths
    • 21.4.10. Weaknesses
    • 21.4.11. Opportunities
    • 21.4.12. Threats
  • 21.5. Janssen Pharmaceuticals
    • 21.5.1. Key Facts
    • 21.5.2. Business Overview
    • 21.5.3. Business Segmentation
    • 21.5.4. Business Strategy
    • 21.5.5. Key Developments
    • 21.5.6. SWOT Analysis
    • 21.5.7. Strengths
    • 21.5.8. Weaknesses
    • 21.5.9. Opportunities
    • 21.5.10. Threats
  • 21.6. Pfizer
    • 21.6.1. Key Facts
    • 21.6.2. Business Overview
    • 21.6.3. Business Segmentation by Revenue 2013
    • 21.6.4. Business Segmentation by Revenue 2012 and 2013
    • 21.6.5. Sales by Geography
    • 21.6.6. Business Strategy
    • 21.6.7. Key Developments
    • 21.6.8. SWOT Analysis
    • 21.6.9. Strengths
    • 21.6.10. Weaknesses
    • 21.6.11. Opportunities
    • 21.6.12. Threats

22. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Rheumatoid Arthritis Drugs Market 2013-2018 (US$ billion)
  • Exhibit 3: Competitive Assessment of Top RA Drugs
  • Exhibit 4: Revenue Share of RA Drugs by Key Vendors 2013
  • Exhibit 5: Global Rheumatoid Arthritis Drugs Market Segmentation by Treatment Approach
  • Exhibit 6: Global Rheumatoid Arthritis Drugs Market Segmentation by Treatment Approach 2013
  • Exhibit 7: Global Rheumatoid Arthritis Drugs Market by Geographical Segmentation 2013
  • Exhibit 8: Global Rheumatoid Arthritis Drugs Market Share Analysis 2013
  • Exhibit 9: AbbVie Inc.: Product Segmentation
  • Exhibit 10: AbbVie Inc.: Revenue by Product Line 2013
  • Exhibit 11: AbbVie Inc.: Revenue Comparison by Product Line 2012 and 2013 (US$ billion)
  • Exhibit 12: AbbVie Inc.: Revenue by Geographical Segmentation 2013
  • Exhibit 13: Amgen: Product Segmentation by Revenue 2013
  • Exhibit 14: Amgen: Geographical Segmentation by Revenue 2013
  • Exhibit 15: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)
  • Exhibit 16: Bristol-Myers Squibb Co.: Sales by Geography 2013
  • Exhibit 17: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 18: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 19: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 20: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 21: Janssen Pharmaceuticals Inc.: Product Segmentation 2013
  • Exhibit 22: Pfizer Inc.: Business Segmentation by Revenue 2013
  • Exhibit 23: Pfizer Inc.: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 24: Pfizer Inc.: Sales by Geography 2013
Back to Top